Chimeric antigen receptor T cell therapies for multiple myeloma

Journal of Hematology & Oncology

Lijuan Chen¹  Lina Zhang¹  Chao Wu¹  Qierra R. Brockman²  Fenghuang Zhan² 

[1] Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital;Department of Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation and Holden Comprehensive Cancer Center, University of Iowa;

关键词: Chimeric antigen receptors;    Multiple myeloma;    Immunotherapy;    Tumor immunology;   

DOI  :  10.1186/s13045-019-0823-5

来源: DOAJ

【 摘 要 】

Abstract Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. Furthermore, the toxicities of CAR-T cell therapy are manageable. This article summarizes recent developments of CAR-T therapy in MM, focusing on promising targets, new technologies, and new research areas. Additionally, a comprehensive overview of antigen selection is presented along with preliminary results and future directions of CAR-T therapy development.

【 授权许可】

Unknown